Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
Public ClinicalTrials.gov record NCT05536973. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Randomized, Double-Masked Phase 2 Study to Assess Safety and Efficacy of ADVM-022 (AAV.7m8-aflibercept) in Anti-VEGF Treatment-Experienced Patients With Neovascular (Wet) Age-related Macular Degeneration (nAMD) [LUNA]
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Neovascular or wet age-related macular degeneration (nAMD) is a degenerative ocular disease associated with the infiltration of abnormal blood vessels in the retina from the underlying choroid layer and is a leading cause of blindness in patients over 65 years of age. The abnormal angiogenic process in nAMD is stimulated and modulated by vascular endothelial growth factor (VEGF). Treatment of nAMD requires frequent intravitreal (IVT) injections of VEGF inhibitors (anti-VEGF) administered every 4-16 weeks. ADVM-022 (AAV.7m8-aflibercept) is a gene therapy product being developed for the treatment of nAMD and offers the potential for sustained intraocular expression of aflibercept following a single IVT injection. ADVM-022 is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with nAMD receiving anti-VEGF therapy in clinical practice.
Study identification
- NCT ID
- NCT05536973
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 69 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 23, 2022 (Actual)
- Primary completion
- Aug 26, 2024 (Actual)
- Completion
- Aug 2028 (Estimated)
- Last update posted
- Aug 22, 2025
2022 – 2028
United States locations
- U.S. sites
- 34
- U.S. states
- 16
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Adverum Clinical Site 178 | Phoenix | Arizona | 85020 | — |
| Adverum Clinical Site 126 | Phoenix | Arizona | 85053 | — |
| Adverum Clinical Site 159 | Tucson | Arizona | 85704 | — |
| Adverum Clinical Site 100 | Beverly Hills | California | 90211 | — |
| Adverum Clinical Site 172 | Encino | California | 91436 | — |
| Adverum Clinical Site 169 | Fullerton | California | 92835 | — |
| Adverum Clinical Site 170 | Pasadena | California | 91105 | — |
| Adverum Clinical Site 174 | Poway | California | 92064 | — |
| Adverum Clinical Site 164 | Riverside | California | 92505 | — |
| Adverum Clinical Site 166 | Sacramento | California | 95817 | — |
| Adverum Clinical Site 175 | Santa Barbara | California | 93103 | — |
| Adverum Clinical Site 116 | Lakewood | Colorado | 80228 | — |
| Adverum Clinical Site 165 | Waterford | Connecticut | 06385 | — |
| Adverum Clinical Site 124 | Deerfield Beach | Florida | 33064 | — |
| Adverum Clinical Site 176 | Fort Lauderdale | Florida | 33308 | — |
| Adverum Clinical Site 168 | Jacksonville | Florida | 32216 | — |
| Adverum Clinical Site 149 | ‘Aiea | Hawaii | 96701 | — |
| Adverum Clinical Site 167 | Detroit | Michigan | 48201 | — |
| Adverum Clinical Site 161 | Royal Oak | Michigan | 48073 | — |
| Adverum Clinical Site 163 | Southaven | Mississippi | 38671 | — |
| Adverum Clinical Site 177 | Omaha | Nebraska | 68105 | — |
| Adverum Clinical Site 119 | Reno | Nevada | 89502 | — |
| Adverum Clinical Site 146 | Cherry Hill | New Jersey | 08034 | — |
| Adverum Clinical Site 171 | Teaneck | New Jersey | 07666 | — |
| Adverum Clinical Site 122 | West Columbia | South Carolina | 29169 | — |
| Adverum Clinical Site 144 | Rapid City | South Dakota | 57701 | — |
| Adverum Clinical Site 101 | Nashville | Tennessee | 37203 | — |
| Adverum Clinical Site 123 | Abilene | Texas | 79606 | — |
| Adverum Clinical Site 154 | Austin | Texas | 78705 | — |
| Adverum Clinical Site 108 | Bellaire | Texas | 77401 | — |
| Adverum Clinical Site 162 | McAllen | Texas | 78503 | — |
| Adverum Clinical Site 151 | San Antonio | Texas | 78240 | — |
| Adverum Clinical Site 107 | The Woodlands | Texas | 77384 | — |
| Adverum Clinical Site 152 | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05536973, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 22, 2025 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05536973 live on ClinicalTrials.gov.